T2 Biosystems, Inc. · OTC:TTOO
T2 Biosystems — Investor Presentation (September 2017)
35 slides from T2 Biosystems's investor presentation, Sep 14, 2017
Slide 1: Transforming Diagnostics, Patient Care & Economics
Transforming Diagnostics, Patient Care & Economics September 2017 (NASDAQ: TTOO)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. Such statements reflect the current views of senior management of T2 Biosystems, Inc. (“we”, “us”, “our”, “T2”, “T2 Biosystems” or the “Company”) and include those about T2’s goals, strategies, plans, objectives, prosp
Slide 3: A platform technology with multiple, billion-dollar franchise opportunities
Transforming Diagnostics, Patient Care & Economics A platform technology with multiple, billion-dollar franchise opportunities T2MR Market Innovative $3B+ Initial market technology with potential broad applications T2Sepsis Solution Provide species-specific results, direct from whole blood, in 3 to
Slide 4: T2MR: Establishing a New Standard in Sepsis Pathogen Detection
T2MR: Establishing a New Standard in Sepsis Pathogen Detection T2Sepsis diagnostics provide a faster and more accurate solution for sepsis pathogen detection >90% Detected1 Species-Specific Results Enables Targeted Therapy 3 to 5 hours Direct to T2Dx 1 to 48 VS. HOURS Species Identification (PCR, MA
Slide 5: Product Pipeline Highlights
Product Pipeline Highlights – Enabled by Highly-Sensitive Detection Directly from whole blood – no requirement for blood culture 2016 2017 2018 and beyond1 T2Candida Panel T2Candida Panel FUNGAL CE & IVD Including pan-Candida T2Bacteria Panel T2Bacteria Panel BACTERIAL Including additional bacteria
Slide 6: T2MR Featured at Tradeshows and in Over Publications Worldwide
T2MR Featured at Tradeshows and in Over 200 Publications Worldwide T2Candida – 91.1% Sensitivity 99.4% Specificity LoD 1-3 CFU/mL T2Candida – 96.4% Sensitivity 99.4% Specificity T2Candida featured as sensitive and specific diagnostic test for invasive candidiasis T2Candida projected to reduce deaths
Slide 7: Shortcomings of Sepsis Management
Shortcomings of Sepsis Management Transforming Diagnostics, Patient Care & Economics | 7
Slide 8: The Facts About Sepsis
The Facts About Sepsis Most expensive hospital-treated condition in the U.S. Contributes to 1 in 2-3 hospital deaths1 Representing $27B in U.S. healthcare $ costs2,3 Claims more lives annually than breast cancer, prostate cancer and AIDS, combined4 More than 1 in 5 surviving patients die within 2 ye
Slide 9: Shortcomings of Current Sepsis Management
Shortcomings of Current Sepsis Management The current process drives up healthcare costs and delays in appropriate treatment 1 – 6+ Days for Diagnostic Results Overuse of Antimicrobial Therapies False Negative Results Quality Metrics Impact Multi-Step, Labor-Intensive Process Transforming Diagnostic
Slide 10: Sepsis Management Today
Sepsis Management Today Empiric therapy dominates treatment decisions because of the time delay of blood culture Accelerate Diagnostics BioMérieux BD Bruker BioFire Luminex 0 Hours 24—72 Hours 72—120 Hours ~27 Hours – Patients Identified Some Blood Culture Positive Final Positive & Negative Blood7 D
Slide 11: T2Sepsis Solution
T2Sepsis Solution Transforming Diagnostics, Patient Care & Economics | 11
Slide 12: T2Sepsis Solution: Rapidly Detecting Species Not Covered by First Line Empiric Therapy
T2Sepsis Solution1: Rapidly Detecting Species Not Covered by First Line Empiric Therapy 30% Ineffectively treated bacterial infections Up to 60% 95% Ineffectively treated effective Rx effective initial 10% fungal infections In hours3 empiric Rx2 T2Candida Panel % Mortality4 T2Bacteria Panel % Mortal
Slide 13: Faster Therapy Saves Lives and Healthcare Costs
Faster Therapy Saves Lives and Healthcare Costs1 Current Situation Day Day Day Day Day Day 2 1 3 4 5 6 Septic Deaths 9,615 people die a week $519,230,769 each week Healthcare costs of care $ $ $ $ $ $ $ $ $ $ 1. Represents the potential healthcare savings and lives saved using the T2Sepsis Solution
Slide 14: T2Bacteria Panel
T2Bacteria Panel Designed to rapidly identify six of the most deadly and prevalent bacteria species often not covered by initial empiric therapy $1.5B+ Market Opportunity FDA Filing, September 2017 CE Mark, July 2017 Completed pivotal study in 11 hospitals sites testing 1,700+ patient samples Sensit
Slide 15: T2Bacteria Addresses Large Unmet Market Need
T2Bacteria Addresses Large Unmet Market Need No FDA-cleared technology that can derive species-specific results directly from blood Bacteria: The Facts ~15,000,000 U.S. patients tested for blood stream infections annually1 8.75M Patients at high risk for a bacterial infection1 Each hour of delayed t
Slide 16: T2Bacteria Clinical Trial Overview
T2Bacteria Clinical Trial Overview1 98.1% 95.8% Overall Sensitivity Overall Specificity Sensitivity by Test Specificity by Test 95% Confidence Interval A. baumannii 97.5% (39/40)87.1%-99.6% E. coli 90.9% (30/33)76.4%-96.9% E. faecium 100.0% (41/41) 91.4%—100.0% K. pneumoniae 100.0% (46/46) 92.3%—100
Slide 17: T2Bacteria Detection of Known Positive Infections
T2Bacteria Detection of Known Positive Infections1 • Of the 102 known positive infections in the clinical pivotal trial, T2Bacteria detected 98 while the paired blood culture only detected 39 T2+ Blood Culture+ Total Paired T2/BC 35 3939 T2+/BC- with 63 063 additional positive culture2 Total known p
Slide 18: Estimated Economic Benefit of the T2Bacteria Panel
Estimated Economic Benefit of the T2Bacteria Panel T2Bacteria Estimated Length of Stay & Cost Reductions with Appropriate Rx in 1st 24 hours if FDA-cleared1 Bacterial Potential Length of Potential Species Stay Reduction Length of (in Days) Stay Savings Hospital ICU E. coli 2 44$22,800 P. aeruginosa
Slide 19: T2Candida Panel
T2Candida Panel The only FDA-cleared non-blood culture-based diagnostic panel for species detection T2Candida Panel Test is covered under T2Candida offers 6.75M high-risk patient approved by the United existing DRG codes where more sensitive market opportunity (US) States Food and Drug hospitals get
Slide 20: T2Candida Addresses Large Unmet Market Need
T2Candida Addresses Large Unmet Market Need 6.75M high-risk patients Only technology that can derive species-specific results directly from blood Candida: The Facts 40% Mortality Rate1 Each hour of delayed treatment increases mortality risk nearly 8%4 50% $130K 40 of infections are missed by Average
Slide 21: T2Candida Panel identifies the five clinically relevant species of Candida
T2Candida Panel identifies the five clinically relevant species of Candida and in clinical trials demonstrated a sensitivity of 91.1%.1 The T2Candida Panel has demonstrated superiority to blood culture and detected 96.4% of patients with candidemia and candidiasis, 2 while blood culture has been sho
Slide 22: Compelling Economics for Hospital Adoption
Compelling Economics for Hospital Adoption Example high-volume hospital scenarios in target market1 Adoption of T2Candida 500 Patients 2,000 Patients 5,000 Patients $7.7M Cost Savings $5.0M Cost Savings $2.4M Cost Savings • Incidence of Candida in • Incidence of Candida in • Incidence of Candida in
Slide 23: T2Candida Panel is Changing Treatment Protocols
T2Candida Panel is Changing Treatment Protocols Growing number of T2Candida customer success stories • Statistically-powered study demonstrating $2.3MM in annual hospital savings • Reduced median ICU length of stay by 7 days (p=0.009) • Reduction in median total length of stay by 4 days/patient (p=0
Slide 24: T2Candida Detecting Invasive Candidiasis
T2Candida Detecting Invasive Candidiasis T2Candida is more sensitive for deep-seated candidiasis than blood-culture based methods • 4 T2+/BC- but BAL culture positive for C. albicans (3) and C. glabrata (1)1 • 12 proven cases of invasive candidiasis T2 positive/blood culture negative2 • Intra-abdomi
Slide 25: Commercial Strategy
Commercial Strategy Transforming Diagnostics, Patient Care & Economics | 25
Slide 26: Significant Opportunity to Expand Target Hospitals
Significant Opportunity to Expand Target Hospitals T2Bacteria Panel Increases Addressable Market of T2MR Technology Platform1 T2Lyme, T2GNR, other pipeline products T2Bacteria & Candida Top 1,200 hospitals T2Candida (only) Top 450 hospitals • T2Bacteria Panel enables rapid diagnostic testing in the
Slide 27: Commercial Strategy
Commercial Strategy1 Continue the global expansion of the T2Candida Panel and plan for T2Bacteria Panel launch U.S. Sales 17 Organization International 7 Distribution Partners 5,000 Total Hospitals Targeted ~1,200 Hospitals Highlight customer success stories to demonstrate the impact that T2MR techn
Slide 28: Commercial Penetration and Goals
Commercial Penetration and Goals1 Commercial traction growing Targeting Top 1,200 Hospitals ~415K Estimated number of high-risk patients in hospital customer base ~130 Hospitals with access to the T2Dx platform Through 6/30/2017 3Q’17 Target 40K Target to increase number of high-risk patients in hos
Slide 29: Upcoming Milestones
Upcoming Milestones1 Ongoing opportunities for value creation 2017 2018+ T2Bacteria Commercial Launch in Europe T2Bacteria Clinical Trial Data T2Bacteria submission to the FDA Expand customer base—secure 40,000+ additional high-risk patients in Q3’17 Increase customer success stories and publication
Slide 30: Strategic Collaboration: Allergan
Strategic Collaboration Endorsement of T2MR detection capabilities from pharma industry leader Overview Agreement with Allergan to create an additional panel on the T2Dx Instrument. The panel will be designed to identify drug resistance to enable physicians to provide targeted therapy faster. Econom
Slide 31: Strategic Collaboration: Canon, Lyme disease panel
Strategic Collaboration Initial focus on development of Lyme disease diagnostic panel Overview Multi-year, strategic agreement to jointly develop a novel diagnostic test panel to rapidly detect Lyme disease which the CDC estimates the annual number of cases in the US to be ~360,000. Economics T2 Bio
Slide 32: Financial Summary
FINANCIAL SUMMARY YTD—As of June 30, 2017 Revenue YTD $1.9M Cash $46.1M Debt Line Availability $10.0M Common Shares Outstanding 30.8M Q2’17 Product Revenue $735K Q2’17 QoQ Sequential Product Growth 16.5% Q2’17 Cash Burn $12.7M Qtrly Cash Burn Decreasing >5% Investors – As of June 30, 20171 Canon Lif
Slide 33: Experienced Management Team
Experienced Management Team T2 management brings years of expertise in the diagnostics industry Name John McDonough Chief Executive Officer Darlene Deptula-Hicks Chief Financial Officer & Senior VP Joanne Spadoro, Ph.D. Chief Operations Officer Stephen Hagan VP, Sales Tom Lowery, Ph.D. Chief Scienti
Slide 34: Investment Highlights
Investment Highlights A platform technology with multiple, billion-dollar franchise opportunities T2MR Market T2Sepsis Solution Innovative $3B+ Initial market Provide species-specific technology with potential results, direct from whole broad applications blood, in 3 to 5 hours1 Reimbursement Robust
Slide 35: Thank You
THANK YOU Transforming Diagnostics, Patient Care & Economics | 35
T2 Biosystems — Investor Presentation (September 2017) on 6ix